The disconnect between the primary policy assumption underpinning the HTA Review, which is that products must be found safe and effective to be funded, demonstrates the extent of this MSAC outcome as a dangerous outlier.
The danger of this outlier is reflected in the disconnect with another policy process
October 18, 2024 Latest NewsBioPharmaComment
Latest Video
New Stories
-
ACT unveils plan to repair New Zealand’s medicines gap by 2033
July 26, 2026 - - Latest News -
The 'Dispatched' Podcast - Series 5, Ep.25
July 24, 2026 - - Podcast -
Finalists named for the 2026 Patient's Choice awards
July 24, 2026 - - Latest News -
The 'end of days' language is just a farcical attempt to shut down discussion
July 24, 2026 - - Latest News -
Australian company moving headquarters to US and restructuring workforce
July 24, 2026 - - Latest News -
Faster processes could push Pharmac's options for investment backlog to 400 within two years
July 23, 2026 - - Latest News -
Bellberry and ASCEPT release checklist for 'new approach methodologies' trials
July 23, 2026 - - Latest News

